The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | Promising agents under investigation for the treatment of MDS and ongoing trials in this space
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, shares some insights into novel agents and combinations being investigated for the treatment of myelodysplastic syndromes (MDS). Dr Sallman first discusses the promise of venetoclax in combination with hypomethylating agents (HMAs) in patients with MDS, and further highlights the Phase III VERONA trial (NCT04401748). Following this, Dr Sallman comments on the promise of sabatolimab in MDS, clinical trials evaluating the use of this agent, and unmet needs in the field. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
